Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at ...
MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases Lead MKI candidates, CBT-001 and CBT-004, demonstrated statistically …